Discover 701 paid clinical trials in Killeen, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 701
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
for
Breast Cancer
Location: Waco TX, Austin TX, Fredericksburg TX, New Braunfels TX,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07062965
Phase 3, Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Location: Waco TX, Austin TX, Irving TX, The Woodlands TX,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07421700
Phase 1, Phase 2, Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
for
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Location: Waco TX, Austin TX, Fort Worth TX, Dallas TX,
Sponsor: Genmab
Sex: Female
Age: 18+
Code: NCT07166094
Phase 3, Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Get alerts for new trials in your area by subscribing now
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
for
Breast Cancer
Location: Waco TX, Austin TX, San Antonio TX, Bedford TX,
Sponsor: Agendia
Sex: All
Age: 18+
Code: NCT03053193
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
for
Cervical Cancer
Location: Waco TX, Austin TX, Fort Worth TX, Arlington TX,
Sponsor: Pfizer
Sex: Female
Age: 18+
Code: NCT06952660
Phase 4, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Round Rock TX, Fort Worth TX, Kingwood TX,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06692738
Phase 3, Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
for
Non-small Cell Lung Cancer,
Location: Round Rock TX, Houston TX, Nashville TN, Gilbert AZ,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05877599
Phase 1, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Round Rock TX, Fort Worth TX, Irving TX, Palestine TX,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase 3, Recruiting
Maestro 1.1 Post-Market Registry
for
Surgery
Location: Cedar Park TX, Denver CO, Jacksonville FL, Orlando FL,
Sponsor: Moon Surgical
Sex: All
Age: 18 - 70+
Code: NCT06103136
Recruiting
Utility of PharmacoGenomics for Reducing Adverse Drug Effects
for
Genetics of Drug Metabolism
Location: Waco TX, Austin TX, League City TX, Lake Charles LA,
Sponsor: Companion Dx Reference Lab, LLC
Sex: All
Age: 18+
Code: NCT02081872
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
for
Ulcerative Colitis, Inflammatory Bowel Diseases
Location: Waco TX, Amarillo TX, Jackson MS, Wichita KS,
Sponsor: Boomerang Medical
Sex: All
Age: 18 - 70+
Code: NCT06571669
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
for
Focal Onset Seizure, Primary Generalized Epilepsy
Location: Round Rock TX, Seabrook TX, Chesterfield MO, Phoenix AZ,
Sponsor: Praxis Precision Medicines
Sex: All
Age: 18 - 70+
Code: NCT06908356
Phase 2, Recruiting
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO